Peptide

CJC-1295

Also known as

CJC-1295 with DAC · CJC-1295 no DAC · CJC-1295 without DAC · Mod GRF 1-29 · Modified GRF 1-29 · DAC:GRF · DAC:GRF (ConjuChem) · CJC1295 · CJC 1295 · CJC-1295 DAC · tetrasubstituted GRF 1-29

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A growth-hormone-release discussion name covering long-acting CJC with DAC and short-acting no-DAC, usually Mod GRF 1-29. They are different compounds.
How it is discussed	Mostly injections under the skin for sleep, recovery and body composition, often with ipamorelin. CJC signals GH release; it is not injected HGH.

Notes

CJC-1295 is a growth-hormone-releasing peptide discussed for sleep, training recovery and body composition, often with ipamorelin. The name covers long-acting DAC and short-acting “no-DAC” products; their amounts and timing differ. Reports range from deeper sleep to no benefit, swelling, fatigue or disrupted sleep.

Two forms share the CJC name. With DAC is the long-acting GHRH analog. DAC attaches it to albumin, a blood protein; “no DAC” usually means Mod GRF 1-29. These are different compounds and cannot share one dose chart. CJC-1295 with or without DAC (Secondhand community claim · Accessed 2026-09-30) · FDA December2024 CJC-1295 evaluation (Official context · Accessed 2026-09-30)

A signal to release GH. GHRH means growth hormone–releasing hormone. This peptide stimulates the pituitary; it is not injected growth hormone or a local injury-healing peptide. Ipamorelin is a separate release signal often paired with it. FDA December2024 CJC-1295 evaluation (Official context · Accessed 2026-09-30)

Subcutaneous injection dominates the reports. That means injection under the skin. Troche/sublingual and occasional intramuscular accounts exist, but their amounts and effects cannot be treated as equivalent to subcutaneous use. My Bad Experience With Growth Hormone Peptides (Personal report · Accessed 2026-09-30) · CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30)

Source context — CJC-1295 with or without DAC: Circulated half-life values; contributors did not measure clearance. Commercially named account contributes. Sermorelin equivalence,50hour release and burnout assertions are not accepted as facts.

Source context — FDA December2024 CJC-1295 evaluation: Opened FDA evaluation and its study summaries, not the original trial full text. DAC salt unspecified in human studies. Formal measurements cannot supply community quick answers.

Source context — My Bad Experience With Growth Hormone Peptides: ME/CFS population, exertion and other treatment confounds; cannot prove peptide caused decline. Troche amount and bioavailability unverified; volume-only dose is not converted.

Source context — CJC-1295+Ipamorelin experience: OP does not explicitly specify DAC status; daily frequency cannot prove identity. AI-assisted translation disclosed. Subreddit promotes an approved-list link; commercial influence is possible. Route change, dieting and stacks confound outcomes.

What people notice

Sleep and daytime energy	Some report deeper sleep or vivid dreams, while others still sleep poorly or develop daytime exhaustion and worse sleep during continued use.
Recovery and appearance	Recovery, skin changes or a fuller look are reported, with little strength change in one DAC account. Swelling can look like size gain.
Appetite	One cutting-phase user noticed more hunger with CJC/ipamorelin; the combination cannot show which ingredient caused it.

Notes

Deeper sleep, sometimes with a cost. A cutting-phase poster noticed fewer awakenings in about a week; another no-DAC/ipamorelin user reported vivid dreams but disruptive daytime sleepiness by week three. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30) · Week-three sleepiness and vivid dreams (Personal report · Accessed 2026-09-30)

Benefits can change during continued use. One commenter described excellent sleep in weeks one/two, fatigue in week three and worsening sleep by week five; heart rate settled over 1–2 weeks after stopping and energy took about a month. This is one person's recovery timeline, not a clearance estimate. Week-three sleepiness and vivid dreams (Personal report · Accessed 2026-09-30)

Better sleep can coexist with worse days. The same cutting thread contains exhaustion and worse cardio despite improved sleep; another reply reports recovery improving later. The no-DAC bad-sleep poster preferred ipamorelin alone. Waiting longer is not a guaranteed fix. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30) · CJC1295 no DAC/Ipa bad sleep (Personal report · Accessed 2026-09-30)

Recovery and physique changes are separate. Users seek less soreness, lean-mass preservation and fat loss. The cutting log initially showed no training change; a DAC user described better recovery but almost no strength gain and substantial water weight. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30) · Experience with CJC-Dac (+ ipa) (Personal report · Accessed 2026-09-30)

Skin and fullness appear in accounts. The week-three user reported modest skin and recovery changes. A fuller look can accompany swelling, so appearance alone cannot establish muscle gain. Week-three sleepiness and vivid dreams (Personal report · Accessed 2026-09-30) · Experience with CJC-Dac (+ ipa) (Personal report · Accessed 2026-09-30)

Appetite can increase too. The cutting-phase user noticed more hunger alongside deeper sleep and facial puffiness. Ipamorelin co-use prevents assigning that change to CJC alone. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30)

Source context — Week-three sleepiness and vivid dreams: Self-reported no-DAC/ipamorelin combination; no independent assay or diagnosis. Hormonal theories in replies are not accepted as fact. Crosspost1ecwsre is the same report, not a second user.

Source context — CJC1295 no DAC/Ipa bad sleep: Subjective self-comparison, not controlled isolation of CJC. Initial short URL returned429; full-title URL body opened.

Source context — Experience with CJC-Dac (+ ipa): Internal timeline/total exposure ambiguity; cannot reconcile5mg total with last-two-weeks statement. Claimed serum concentration is arithmetic, not a reported measured lab value. Community has promotional links.

Doses people talk about

No-DAC charts	100–300 mcg per under-skin administration, once at bedtime or 1–3 times/day. The per-use amount is not automatically the daily total.
No-DAC/ipamorelin pairs	One account: 150 mcg CJC + 200 mcg ipamorelin nightly, five nights/week. Another: 100/200 mcg morning and bedtime, totaling 200 mcg CJC + 400 mcg ipamorelin on those days.
DAC reports	1–2 mg total/week appears as 1 mg once or twice weekly; another account uses 0.5 mg twice weekly. Older charts separately claim 1–2 mg per injection once or twice weekly.
Blend arithmetic	100+100 mcg is 200 mcg combined, not 200 mcg of each. Equal-ratio blends and ipamorelin-heavy blends need their own component amounts.

Notes

No DAC: 100–300 mcg per subcutaneous use. The preserved discussion band includes 100 or 200 mcg amounts, used once at bedtime or 1–3 times/day. That is per administration, not automatically the daily total.

Actual pair reports: 150/200 mcg and 100/200 mcg. One user described 150 mcg no-DAC plus 200 mcg ipamorelin nightly, five nights/week. Another used 100/200 mcg morning and bedtime—200 mcg CJC and 400 mcg ipamorelin on those days—with continued poor sleep. Week-three sleepiness and vivid dreams (Personal report · Accessed 2026-09-30) · CJC1295 no DAC/Ipa bad sleep (Personal report · Accessed 2026-09-30)

DAC: 1–2 mg weekly-style talk. A reply gives 1–2 mg total/week as 1 mg once or twice weekly; a separate user reports 0.5 mg twice/week. The original also describes 1–2 mg per injection once or twice/week and lower 300–600 mcg once/twice-weekly charts. These are distinct claims, not one validated band. Cjc with dac (Secondhand community claim · Accessed 2026-09-30) · Experience with CJC-Dac (+ ipa) (Personal report · Accessed 2026-09-30)

1:1 blends: total is not each ingredient. Original 5/5 mg or 10/10 mg blends contain equal component masses. 100+100 mcg is 200 mcg combined; 200+200 is 400 mcg. Older 200–500 mcg combined-use talk and ipamorelin-heavy 150–300 mcg plus 100–200 mcg no-DAC variants must keep their ratios.

Source context — CJC1295 no DAC/Ipa bad sleep: Subjective self-comparison, not controlled isolation of CJC. Initial short URL returned429; full-title URL body opened.

Source context — Cjc with dac: Reply is a generalized chart claim, not measured use or community prevalence. Lower-dose dismissal is opinion; promotional subreddit context.

Half-life, onset & duration

Felt onset	Sleep changes are reported from the first night to about five weeks. Physique stories describe 6–8 weeks or months amid training, diet and fluid changes.
Felt duration	No dependable one-dose sleep or recovery window. Benefit, fatigue and sleep quality can change during continued use.
Half-life	No-DAC's 25–30 minutes is circulated without verified human clearance here. Formal DAC repeated-dose research gives 5.4–9.2 days; that does not measure days of better sleep.

Notes

Sleep reports: early nights to several weeks. The original includes first-night dreams; the cutting poster noticed deeper sleep within about a week. A Phoenix Rising account noticed benefit at week five, while another user still slept poorly after two weeks. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30) · My Bad Experience With Growth Hormone Peptides (Personal report · Accessed 2026-09-30) · CJC1295 no DAC/Ipa bad sleep (Personal report · Accessed 2026-09-30)

Physique stories: 6–8 weeks or months. That window is preserved community observation, confounded by training, calories, stacks and fluid shifts. An unchanged early physique does not justify escalation.

No dependable one-dose benefit window. These reports do not establish an hours-long duration for sleep or recovery. The short peptide estimate and DAC's week-long figure cannot answer that felt-effect question. iPam and CJC question (Personal report · Accessed 2026-09-30) · Week-three sleepiness and vivid dreams (Personal report · Accessed 2026-09-30) · Experience with CJC-Dac (+ ipa) (Personal report · Accessed 2026-09-30)

No DAC: about 25–30 minutes is circulated. Original notes and opened naming threads repeat this estimate. No human clearance study establishing that number for these users' Mod GRF products was verified. It does not measure how long sleep or recovery benefits last. CJC-1295 with or without DAC (Secondhand community claim · Accessed 2026-09-30)

DAC measurements are supporting context. FDA's review describes repeated-dose half-lives 5.4–9.2 days, IGF-1 elevation 9–11 days after single use and through day 28 with repeated use. It summarizes healthy-adult subcutaneous research, not these community products or a measured duration of sleep benefits. FDA December2024 CJC-1295 evaluation (Official context · Accessed 2026-09-30)

Source context — CJC1295 no DAC/Ipa bad sleep: Subjective self-comparison, not controlled isolation of CJC. Initial short URL returned429; full-title URL body opened.

Source context — iPam and CJC question: Amount unstated. Symptom onset only; no duration measurement, product verification or causal diagnosis.

Cycles people discuss

Course lengths	8–12 weeks, sometimes 12–16, with roughly four weeks off; shorter probes and equal on/off patterns also circulate. These are reported practices, not safety-tested courses.
Weekly breaks and restarts	Five nights/week, daily use and months-long DAC accounts coexist. A severe restart reaction occurred after two months on/one off; a break did not ensure tolerance.

Notes

8–12 weeks; some 12–16 week blocks. These original community patterns include roughly four weeks off, equal on/off variants and shorter 4–6 week probes. Opened logs include planned 8- and 12-week courses; these are reported practices, not safety-tested courses. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30)

Five days on/two off; daily or months-long use. The week-three no-DAC user followed five nights/week. Older DAC accounts run weekly over months; longer no-DAC routines also exist. Cost, convenience and desensitization theories explain breaks in discussion, but do not validate them. Week-three sleepiness and vivid dreams (Personal report · Accessed 2026-09-30)

Two months on/one month off did not ensure tolerance. A restart report describes severe symptoms despite a previously favorable run. Its form and 300 mcg/day blend allocation are unclear. There is no established steroid-style post-cycle therapy or reliable restart rule here. My experience with cjc/ipamorelin (Personal report · Accessed 2026-09-30)

Source context — My experience with cjc/ipamorelin: Form and blend ratio unstated;300mcg/day and200mcg occasion cannot be assigned to each ingredient. Cause not diagnosed. Replies' appendix and allergy theories are not accepted.

Stacks

Ipamorelin	No-DAC plus ipamorelin is a recurring pair; weekly DAC with daily ipamorelin is a separate pattern.
Other combinations	GHRP-2, GHRP-6, hexarelin and BPC-157/TB-500 appear in older stacks. More hunger and side-effect debates accompany the older GH-release pairings.

Notes

CJC no-DAC + Ipamorelin: Default dual stack and the most common premixed blend on research markets; 1:1 mcg pulses 1–3× daily. [community]

CJC with DAC + Ipamorelin: Weekly long-acting GHRH + daily GHRP hybrid for fewer pins; pulse purists often prefer pure no-DAC dual dosing. [community]

Stacks make the credit hard to assign. Older GHRP-2/6/hexarelin pairings bring additional hunger and side-effect debates; MK-677, BPC-157/TB-500 and sleep habits also appear. IGF-1/glucose checks after 2–3 months are discussed, but labs cannot isolate each ingredient or verify a vial.

+ BPC-157 / TB-500 (“Wolverine” adjacency): “Recover + sleep + heal” lifestyle stacks — heavy confounding; not a formal GH protocol. [community]

Watch for

Swelling and heart symptoms	Puffiness, tingling, headache, racing heart and injection irritation are reported. One restart account included fainting and throat swelling, which warrant urgent medical assessment.
Glucose and long-term uncertainty	Glucose/insulin concerns, growth-signaling questions and pregnancy/breastfeeding unknowns remain. Natural-pulse claims do not establish athletic safety.
Vial identity	DAC/no-DAC errors and blend ratios change the comparison. A flush or vivid dream does not verify purity.

Notes

Swelling, tingling, headache or racing heart. Facial/hand puffiness, numbness, stiffness, warmth and injection-site irritation appear in reports. FDA separately flags increased heart rate, systemic vasodilation and immune/impurity concerns. Experience with CJC-Dac (+ ipa) (Personal report · Accessed 2026-09-30) · iPam and CJC question (Personal report · Accessed 2026-09-30) · FDA: bulk substances that may present significant safety risks (Official context · Accessed 2026-09-30)

Fainting and throat swelling are serious. The restart poster reported those symptoms with blurry vision. They warrant urgent medical assessment rather than an assumption that the body is adjusting or that a stronger reaction means a better product. My experience with cjc/ipamorelin (Personal report · Accessed 2026-09-30)

Glucose and growth signaling matter. Original discussion flags glucose/insulin concerns, active-cancer risk questions and unknown pregnancy/breastfeeding safety. These are cautions, not proof that CJC caused cancer or that a reassuring lab makes prolonged use safe.

“Natural pulses” do not establish safety. No-DAC preference, DAC “GH bleed” and pituitary-burnout arguments are community theories. A human study summarized by FDA found pulses persisted with DAC. Neither form has demonstrated long-term athletic safety. CJC-1295 with or without DAC (Secondhand community claim · Accessed 2026-09-30) · FDA December2024 CJC-1295 evaluation (Official context · Accessed 2026-09-30)

Labels and reactions do not verify a vial. DAC/no-DAC mistakes, unknown contents and blend ratios make comparisons unreliable. A flush or vivid dream is not a purity test; adding other GHRH peptides is described as redundant in the original discussion. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30)

Source context — iPam and CJC question: Amount unstated. Symptom onset only; no duration measurement, product verification or causal diagnosis.

Source context — FDA: bulk substances that may present significant safety risks: Agency risk summary, not a frequency estimate or determination that any particular forum symptom was caused by CJC.

Full notes

What the name means

Two forms share the CJC name. With DAC is the long-acting GHRH analog. DAC attaches it to albumin, a blood protein; “no DAC” usually means Mod GRF 1-29. These are different compounds and cannot share one dose chart. Reddit · r/Peptides Official context
A signal to release GH. GHRH means growth hormone–releasing hormone. This peptide stimulates the pituitary; it is not injected growth hormone or a local injury-healing peptide. Ipamorelin is a separate release signal often paired with it. Official context Community
Subcutaneous injection dominates the reports. That means injection under the skin. Troche/sublingual and occasional intramuscular accounts exist, but their amounts and effects cannot be treated as equivalent to subcutaneous use. Community Personal report Reddit · r/BodyHackGuide

What people hope to get

Deeper sleep, sometimes with a cost. A cutting-phase poster noticed fewer awakenings in about a week; another no-DAC/ipamorelin user reported vivid dreams but disruptive daytime sleepiness by week three. Reddit · r/BodyHackGuide Personal report
Recovery and physique changes are separate. Users seek less soreness, lean-mass preservation and fat loss. The cutting log initially showed no training change; a DAC user described better recovery but almost no strength gain and substantial water weight. Reddit · r/BodyHackGuide Personal report
Skin and fullness appear in accounts. The week-three user reported modest skin and recovery changes. A fuller look can accompany swelling, so appearance alone cannot establish muscle gain. Personal report Personal report
Appetite can increase too. The cutting-phase user noticed more hunger alongside deeper sleep and facial puffiness. Ipamorelin co-use prevents assigning that change to CJC alone. Reddit · r/BodyHackGuide

Doses people discuss

No DAC: 100–300 mcg per subcutaneous use. The preserved discussion band includes 100 or 200 mcg amounts, used once at bedtime or 1–3 times/day. That is per administration, not automatically the daily total. Community
Actual pair reports: 150/200 mcg and 100/200 mcg. One user described 150 mcg no-DAC plus 200 mcg ipamorelin nightly, five nights/week. Another used 100/200 mcg morning and bedtime—200 mcg CJC and 400 mcg ipamorelin on those days—with continued poor sleep. Personal report Personal report
DAC: 1–2 mg weekly-style talk. A reply gives 1–2 mg total/week as 1 mg once or twice weekly; a separate user reports 0.5 mg twice/week. The original also describes 1–2 mg per injection once or twice/week and lower 300–600 mcg once/twice-weekly charts. These are distinct claims, not one validated band. Reddit · r/BodyHackGuide Personal report Community
1:1 blends: total is not each ingredient. Original 5/5 mg or 10/10 mg blends contain equal component masses. 100+100 mcg is 200 mcg combined; 200+200 is 400 mcg. Older 200–500 mcg combined-use talk and ipamorelin-heavy 150–300 mcg plus 100–200 mcg no-DAC variants must keep their ratios. Community
Weekly DAC plus daily ipamorelin is another pattern. Original discussion pairs 1–2 mg DAC weekly with 100–300 mcg ipamorelin daily or more often. Trial-derived 30 mcg/kg arithmetic also circulates; it is not evidence for an effective bodybuilding amount. Community

Half-life discussed in the community

No DAC: about 25–30 minutes is circulated. Original notes and opened naming threads repeat this estimate. No human clearance study establishing that number for these users' Mod GRF products was verified. It does not measure how long sleep or recovery benefits last. Community Reddit · r/Peptides
DAC: about a week, sometimes “up to 8 days.” The forum repeats a number originating in healthy-adult DAC research, not community self-measurement. Repeated-dose exposure can accumulate; weekly habits are not proof of a suitable interval. Reddit · r/Peptides Personal report

When people notice something

About 2 minutes: a head-rush report. A person adding no-DAC to previously tolerated ipamorelin reported head pressure shortly after injection; amount was unstated. This is symptom onset, not proof of benefit or purity. Personal report
Sleep reports: early nights to several weeks. The original includes first-night dreams; the cutting poster noticed deeper sleep within about a week. A Phoenix Rising account noticed benefit at week five, while another user still slept poorly after two weeks. Community Reddit · r/BodyHackGuide Personal report Personal report
Physique stories: 6–8 weeks or months. That window is preserved community observation, confounded by training, calories, stacks and fluid shifts. An unchanged early physique does not justify escalation. Community

How long effects seem to last

No dependable one-dose benefit window. These reports do not establish an hours-long duration for sleep or recovery. The short peptide estimate and DAC's week-long figure cannot answer that felt-effect question. Personal report Personal report Personal report
Benefits can change during continued use. One commenter described excellent sleep in weeks one/two, fatigue in week three and worsening sleep by week five; heart rate settled over 1–2 weeks after stopping and energy took about a month. This is one person's recovery timeline, not a clearance estimate. Personal report
Water weight may fade after stopping. A no-DAC blend user reported 2–3 lb gain that dropped fairly quickly off it, without a precise day count. The DAC user reported losing more than 10 lb of apparent water after stopping, with an unclear exposure timeline. Personal report Personal report

Courses and breaks people describe

8–12 weeks; some 12–16 week blocks. These original community patterns include roughly four weeks off, equal on/off variants and shorter 4–6 week probes. Opened logs include planned 8- and 12-week courses; these are reported practices, not safety-tested courses. Community Reddit · r/BodyHackGuide
Five days on/two off; daily or months-long use. The week-three no-DAC user followed five nights/week. Older DAC accounts run weekly over months; longer no-DAC routines also exist. Cost, convenience and desensitization theories explain breaks in discussion, but do not validate them. Personal report Community
Two months on/one month off did not ensure tolerance. A restart report describes severe symptoms despite a previously favorable run. Its form and 300 mcg/day blend allocation are unclear. There is no established steroid-style post-cycle therapy or reliable restart rule here. Personal report Community

Watch for

Swelling, tingling, headache or racing heart. Facial/hand puffiness, numbness, stiffness, warmth and injection-site irritation appear in reports. FDA separately flags increased heart rate, systemic vasodilation and immune/impurity concerns. Community Personal report Personal report Official context
Fainting and throat swelling are serious. The restart poster reported those symptoms with blurry vision. They warrant urgent medical assessment rather than an assumption that the body is adjusting or that a stronger reaction means a better product. Personal report
Glucose and growth signaling matter. Original discussion flags glucose/insulin concerns, active-cancer risk questions and unknown pregnancy/breastfeeding safety. These are cautions, not proof that CJC caused cancer or that a reassuring lab makes prolonged use safe. Community
“Natural pulses” do not establish safety. No-DAC preference, DAC “GH bleed” and pituitary-burnout arguments are community theories. A human study summarized by FDA found pulses persisted with DAC. Neither form has demonstrated long-term athletic safety. Reddit · r/Peptides Official context
Labels and reactions do not verify a vial. DAC/no-DAC mistakes, unknown contents and blend ratios make comparisons unreliable. A flush or vivid dream is not a purity test; adding other GHRH peptides is described as redundant in the original discussion. Community Reddit · r/BodyHackGuide

What formal measurements add

DAC measurements are supporting context. FDA's review describes repeated-dose half-lives 5.4–9.2 days, IGF-1 elevation 9–11 days after single use and through day 28 with repeated use. It summarizes healthy-adult subcutaneous research, not these community products or a measured duration of sleep benefits. Official context

What the reports help explain

Bedtime is a habit, not a universal sleep solution. Meal threads debate 2–3 hours before and 30–60 minutes after; the original includes shorter 30–90 minute claims and morning/post-workout variants. One user found dinner timing burdensome. Those rituals do not establish a necessary fasting window. Reddit · r/Peptides Community
Better sleep can coexist with worse days. The same cutting thread contains exhaustion and worse cardio despite improved sleep; another reply reports recovery improving later. The no-DAC bad-sleep poster preferred ipamorelin alone. Waiting longer is not a guaranteed fix. Reddit · r/BodyHackGuide Personal report
Fewer injections versus more adjustable exposure. DAC appeals to people avoiding frequent injections; no-DAC users favor shorter pulses and partner timing. The DAC log reports unnoticeable no-DAC effects but intolerable DAC swelling: convenience and benefit can pull in different directions. Personal report Community
Stacks make the credit hard to assign. Older GHRP-2/6/hexarelin pairings bring additional hunger and side-effect debates; MK-677, BPC-157/TB-500 and sleep habits also appear. IGF-1/glucose checks after 2–3 months are discussed, but labs cannot isolate each ingredient or verify a vial. Community Community
A favorable beginning does not settle a long run. An ExcelMale contributor reported sleep and 8 lb weight loss over two months, then slower loss. The ME/CFS forum describes initial benefit followed by major decline with exertion confounds; its troche account cannot validate injected dosing. Personal report Personal report